CLSD

Clearside Biomedical Inc

CLSD, USA

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

https://clearsidebio.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CLSD
stock
CLSD

Should I hold or sell CLSD now - Quarterly Earnings Report & Weekly Market Pulse Alerts bollywoodhelpline.com

Read more →
CLSD
stock
CLSD

Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Rating of “Hold” from Brokerages Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$60

Analyst Picks

Strong Buy

4

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.08

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

11.07 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-51.30 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,730.85 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 1.28% of the total shares of Clearside Biomedical Inc

1.

Vanguard Group Inc

(0.2856%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(0.1638%)

since

2025/07/31

3.

Carmignac Gestion

(0.1281%)

since

2025/06/30

4.

Carmignac Pf L-S Eurp Eqs F EUR Acc

(0.1281%)

since

2025/06/30

5.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0748%)

since

2025/07/31

6.

Geode Capital Management, LLC

(0.0671%)

since

2025/06/30

7.

BlackRock Inc

(0.0531%)

since

2025/06/30

8.

GSA Capital Partners LLP

(0.0453%)

since

2025/06/30

9.

Renaissance Technologies Corp

(0.0422%)

since

2025/06/30

10.

Fidelity Extended Market Index

(0.0319%)

since

2025/07/31

11.

First Manhattan Co. LLC

(0.0291%)

since

2025/06/30

12.

State Street Corp

(0.0225%)

since

2025/06/30

13.

Bridgeway Capital Management, LLC

(0.0174%)

since

2025/06/30

14.

Bridgeway Ultra-Small Company Market

(0.0174%)

since

2025/06/30

15.

Northern Trust Corp

(0.0141%)

since

2025/06/30

16.

Fidelity Total Market Index

(0.0118%)

since

2025/07/31

17.

Assenagon Asset Management SA

(0.0112%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(0.0111%)

since

2025/06/30

19.

Extended Equity Market Fund K

(0.0104%)

since

2025/06/30

20.

PNC Financial Services Group Inc

(0.0092%)

since

2025/06/30

21.

Brown Wealth Management, LLC

(0.0085%)

since

2025/06/30

22.

Fidelity Series Total Market Index

(0.0082%)

since

2025/07/31

23.

Northeast Financial Consultants, Inc

(0.0079%)

since

2025/06/30

24.

NT Ext Equity Mkt Idx Fd - L

(0.0077%)

since

2025/06/30

25.

Northern Trust Extended Eq Market Idx

(0.0077%)

since

2025/06/30

26.

Susquehanna International Group, LLP

(0.0076%)

since

2025/06/30

27.

CapTrust Financial Advisors

(0.0074%)

since

2025/06/30

28.

Spartan Extended Market Index Pool F

(0.0074%)

since

2025/07/31

29.

NT Ext Equity Mkt Idx Fd - NL

(0.006%)

since

2025/06/30

30.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0049%)

since

2025/07/31

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0047%)

since

2025/06/30

32.

Fidelity Nasdaq Composite Index

(0.004%)

since

2025/07/31

33.

Spartan Total Market Index Pool G

(0.0038%)

since

2025/07/31

34.

Invesco Technology S&P US Sel Sec ETF

(0.0038%)

since

2025/07/31

35.

Stifel Financial Corp

(0.0034%)

since

2025/06/30

36.

Investor's Fiduciary Advisor Network, LLC

(0.0029%)

since

2025/06/30

37.

UBS Group AG

(0.0028%)

since

2025/06/30

38.

Vanguard Balanced Index Inv

(0.0028%)

since

2025/07/31

39.

Blackrock US Eq Mkt Fund CF

(0.0024%)

since

2025/07/31

40.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0022%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.14

EPS Estimate

-0.0671

EPS Difference

-1.0729

Surprise Percent

-1598.9568%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.